Breast Cancer Risk Reduction and Counseling: Lifestyle, Chemoprevention, and Surgery

Author:
Martin C. Mahoney From the Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, New York; the Department of Social and Preventive Medicine, School of Public Health & Health-Related Professions, University at Buffalo, Buffalo, New York; and the Department of Family Medicine, School of Medicine & Biomedical Sciences, University at Buffalo, Buffalo, New York.

Search for other papers by Martin C. Mahoney in
Current site
Google Scholar
PubMed Close
 MD, PhD
Volume/Issue:
Volume 5: Issue 8
Online Publication Date:
Sep 2007
DOI:
https://doi.org/10.6004/jnccn.2007.0071
Full access

Qualitative and quantitative approaches to risk assessment are useful for identifying women at increased risk for developing breast cancer for whom genetics consultation, individualized surveillance recommendations, or chemoprevention may be appropriate. A comprehensive medical and family history review can be used to stratify women into categories of breast cancer risk. A quantitative estimate of the probability of developing breast cancer can be determined using risk assessment tools, such as the Gail and Claus models. Women at increased risk for breast cancer may benefit from individualized approaches to breast cancer risk reduction. Prevention strategies for reducing breast cancer risk include lifestyle modifications, chemoprevention, surgical approaches, and pharmacotherapy.

Correspondence: Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute - Carlton 307, Elm and Carlton Streets, Buffalo, NY 14263. E-mail: Martin.Mahoney@RoswellPark.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    American Cancer Society. Cancer Facts & Figures 2007. Available at: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp. Accessed July 19, 2007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Surveillance, Epidemiology, and End Results (SEER) Program. DevCan database: SEER 17 Incidence and Mortality, 2000–2003. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available at: http://www.seer.cancer.gov. Accessed July 19, 2007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003;237:474–482.

  • 4.

    Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007;96:11–15.

  • 5.

    Whittemore AS, Gong G, John EM et al.. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 2004;13:2078–2083.

  • 6.

    Malone KE, Daling JR, Doody DR et al.. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black american women ages 35 to 64 years. Cancer Res 2006;66:8297–8308.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Bhatia S, Robison LL, Oberlin O et al.. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745–751.

  • 8.

    Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25–31.

  • 9.

    Travis LB, Hill DA, Dores GM et al.. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465–475.

  • 10.

    Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, version 2. Available at: http://www.survivorshipguidelines.org/. Accessed July 19, 2007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Saslow D, Boetes C, Burke W et al.. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75–89.

  • 12.

    Gail MH, Brinton LA, Byar DP et al.. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879–1886.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232–242.

  • 14.

    van Asperen CJ, Jonker MA, Jacobi CE et al.. Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev 2004;13:87–93.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643–651.

  • 16.

    Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993;28:115–120.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145–158.

  • 18.

    Chen J, Pee D, Ayyagari R et al.. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98:1215–1226.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Barlow WE, White E, Ballard-Barbash R et al.. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204–1214.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Rossouw JE, Anderson GL, Prentice RL et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–333.

  • 21.

    Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–332.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Fisher B, Costantino JP, Wickerham DL et al.. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Vogel VG, Costantino JP, Wickerham DL et al.. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727–2741.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Cauley JA, Norton L, Lippman ME et al.. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125–134.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Martino S, Cauley JA, Barrett-Connor E et al.. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–1761.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Barrett-Connor E, Mosca L, Collins P et al.. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–137.

  • 27.

    Fisher B, Costantino JP, Wickerham DL et al.. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652–1662.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Ettinger B, Black DM, Mitlak BH et al.. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Delmas PD, Bjarnason NH, Mitlak BH et al.. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–1647.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Cummings SR, Eckert S, Krueger KA et al.. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189–2197.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 2006;7:2301–2307.

  • 32.

    Armstrong K, Quistberg DA, Micco E et al.. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260–2265.

  • 33.

    Bevers TB, Armstrong DK, Arun B et al.. NCCN breast cancer risk reduction clinical practice guidelines in oncology, version 1, 2007. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Last accessed 1 June 2007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Coombes RC, Hall E, Gibson LJ et al.. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Goss PE, Ingle JN, Martino S et al.. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Baum M, Budzar AU, Cuzick J et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–2139.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003;14:915–922.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005;68:40–47.

  • 39.

    Cook NR, Lee IM, Gaziano JM et al.. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47–55.

  • 40.

    Hartmann LC, Schaid DJ, Woods JE et al.. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77–84.

  • 41.

    Hartmann LC, Sellers TA, Schaid DJ et al.. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633–1637.

Copyright:
Copyright © 2007 by the National Comprehensive Cancer Network
Page Numbers:
9
Article Category:
Research Article
Received:
08 Apr 2007
Accepted:
16 Apr 2007
Print Publication Date:
01 Sep 2007
Online Publication Date:
Sep 2007
Keywords:
Breast cancer; prevention; clinical trials; tamoxifen; raloxifene; chemoprevention

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 757 477 10
PDF Downloads 407 153 7
EPUB Downloads 0 0 0